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Abstract
Objective. To compare the effects of aggressive tight control therapy and conventional care on radio-
graphic progression and disease activity in patients with early mild inflammatory arthritis.
Methods. Patients with two to five swollen joints, Sharpvan der Heijde radiographic score (SHS) <5 and
symptom duration 42 years were randomized between two strategies. Patients with a definite non-RA
diagnosis were excluded. The protocol of the aggressive group aimed for remission (DAS<1.6), with
consecutive treatment steps: MTX, addition of adalimumab and combination therapy. The conventional
care group followed a strategy with traditional DMARDs (no prednisone or biologics) without DAS-based
guideline. Outcome measures after 2 years were SHS (primary), remission rate and HAQ score
(secondary).
Results. Eighty-two patients participated (60% ACPA positive). In the aggressive group (n=42), 19
patients were treated with adalimumab. In the conventional care group (n=40), 24 patients started with
hydroxychloroquin (HCQ), 2 with sulfasalazine (SSZ) and 14 with MTX. After 2 years, the median SHS
increase was 0 [interquartile range (IQR) 01.1] and 0.5 (IQR 02.5), remission rates were 66 and 49% and
HAQ decreased with a mean of  0.09 (0.50) and  0.25 (0.59) in the aggressive and conventional care
group, respectively. All comparisons were non-significant.
Conclusion. In patients with early arthritis of two to five joints, both aggressive tight-control therapy
including adalimumab and conventional therapy resulted in remission rates around 50%, low radiographic
damage and excellent functional status after 2 years. However, full disease control including radiographic
arrest in all patients remains an elusive target even in moderately active early arthritis.
Trial registration. Dutch Trial Register, http://www.trialregister.nl/, NTR 144.
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Introduction
The early and aggressive treatment of patients with RA is
increasingly successful, particularly with combinations of
DMARDs containing anti-TNF therapy [15]. Among the
results are percentages of sustained remission of  40%,
excellent functional status and nearly complete arrest
of radiological damage progression. In an attempt to
explain these better results than had been attained
before in RA of longer duration, the concept of a
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early suppression of active inflammation produces
long-term benefits [6].
Intensive therapy, preferably with a combination of
drugs, therefore, is a well-established treatment strategy
for patients with early active RA. However, the optimal
strategy for patients presenting with only a few inflamed
joints is not yet clear. This category of patients is more
difficult to study due to the problem of classifying these
patients as having RA or undifferentiated arthritis (UA) [7].
In recognition of this issue, a combined task force of ACR
and EULAR has developed new classification criteria for
RA [8]. One of the objectives of these criteria is to increase
the sensitivity for the diagnosis RA in early UA in order to
facilitate the conduction of clinical trials in this category of
patients. Other aspects to consider in trials in this group of
patients are that around half of patients with UA will remit
within 12 years [913], that it is inherently less possible to
demonstrate a reduction of an already low disease activ-
ity, and finally that any toxicity of treatment is less accept-
able since it is occurring in patients with only mildly active
disease.
In a preceding study, we have shown that patients with
more severe forms of UA are under-treated in comparison
with patients with RA [9]. One clinical trial has shown that
UA patients treated with MTX vs placebo have less pro-
gression to RA (according to 1987 ACR criteria [14]) and
less progression of radiographic erosions, but these differ-
ences were confined to the subgroup of ACPA-positive
patients [15]. On the other hand, in early RA good results
can also be obtained with the milder drug hydroxychloro-
quin (HCQ) [16]. The present 2-year trial [Strategies in Early
Arthritis Management (STREAM)] investigated whether the
approach of early aggressive therapy was also effective in
arthritis patients presenting with only moderately active
disease, i.e. in those patients who would not meet the
usual inclusion criteria for trials in active RA.
Patients and methods
Patients
Eligible patients were 518 years, with a symptom dur-
ation of 42 years. In addition, they had to have two to
five swollen joints and a total Sharpvan der Heijde radio-
graphic score (SHS) [17] <5. Patients did not have to meet
the 1987 ACR criteria for RA. Exclusion criteria were prior
treatment with a DMARD, except for HCQ, the use of CSs
in the last 3 months or an IA injection with CSs in the last
month. In addition, patients with bacterial arthritis,
crystal-induced arthritis, PsA, ReA, OA or arthritis due to
sarcoidosis or another systemic autoimmune disease
other than RA, as well as pregnant patients and patients
with a wish to conceive during the study were excluded.
The patients were recruited from the rheumatology clin-
ics of the Jan van Breemen Institute and the VU University
Medical Center in Amsterdam, The Netherlands. The
study was approved by the local institutional review
board [Medisch Ethische Toetsingscommissie van
Slotervaartziekenhuis en Reade (formerly Jan van
Breemen Institute)] and all patients gave written informed
consent. The trial registration number is NTR 144.
Study design and treatment algorithm
The study was designed as analogous to the Behandel
Strategiee ¨n (BeSt) study of treatment strategies in early
active RA [3], and compared two treatment strategies in
a single-blind clinical trial. Whereas in the BeSt study the
criterion for a change of therapy was a DAS >2.4, here we
used a lower DAS threshold for a change of therapy of 1.6,
as disease activity is inherently lower in this group of pa-
tients. Also, the goal of the intervention was to achieve and
maintain remission, which is defined as a DAS<1.6 [18].
The patients were randomized in blocks of 10 into one
of two treatment groups: (i) aggressive therapy and
(ii) conventional care. In the aggressive group, therapy
was aimed at achieving and maintaining a DAS (44-joint
score) of <1.6, which is considered to represent remission
[18]. Every 3 months the DAS was performed by a re-
search nurse who was blinded to the allocated treatment
group. Treatment was started with oral MTX 15mg/week.
If the DAS was 51.6 at a given time point, the therapy was
changed (see also Table 1). The predefined steps were:
increase in MTX to 25mg/week; MTX 25mg/week com-
bined with adalimumab 40mg/2 week; MTX 25mg/week
combined with adalimumab 40mg/week; a combination
of MTX 25mg/week, SSZ 2000mg/day and HCQ
400mg/day; a combination of MTX 25mg/week,
SSZ 2000mg/day, HCQ 400mg/day and prednisone
7.5mg/day; leflunomide (LEF) 20mg/day and i.m. gold
50mg/week. If the DAS was <1.6 at one time point the
treatment remained unchanged. If the DAS was <1.6 at
two consecutive time points the following actions were
taken, depending on the treatment step where the patient
was at that moment: MTX 15mg/week was decreased
from 2.5mg/2 weeks to 0mg/week after 3 months; MTX
25mg/week was decreased from 2.5mg/2 weeks to
10mg/week after 3 months; adalimumab 40mg/2 weeks
was stopped; adalimumab 40mg/week was decreased to
40mg/2 weeks; HCQ was decreased from 200mg/8
weeks to 0; if remission was sustained after 3 months
SSZ was decreased subsequently from 500mg/4 weeks
to 0; if remission was sustained after 3 months MTX was
decreased from 2.5mg/2 weeks to 0; prednisone 7.5mg/
day was decreased to 0mg in 7 weeks; LEF was
decreased to 10mg/day; and if remission was sustained
after 3 months LEF was stopped; gold was decreased to
50mg/2 weeks, if DAS remained <1.6; and gold was
decreased to 50mg/4 weeks; if remission was sustained,
gold was stopped. If at any time point the DAS was 51.6
the last effective treatment was restarted. In case of
intolerance to a DMARD, the highest tolerated dose was
used and, if DAS was 51.6 at the next visit, the patient
went on to the next step.
Conventional care was treatment according to the treat-
ing rheumatologist’s preference. The rheumatologist had
access to the DAS, but was not prompted to make treat-
ment decisions based on the DAS. In order to maintain a
certain amount of homogeneity in the treatment of the
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between the groups in terms of therapy, the following
order of drugs was suggested to the treating rheumatolo-
gist: HCQ, SSZ, MTX and LEF. Furthermore, the treating
physician could only change therapy if the DAS was >2.4
at the 3-month assessment time points and after consult-
ing the trial supervisor (D.vS.). During the course of the
inclusion period (June 20042007), the conventional care
of RA became more aggressive in general. Therefore, from
August 2005 onwards, after the inclusion of 25 patients,
the treating physician was allowed to start therapy with
MTX in the conventional care group if deemed necessary.
IA CS injections were not regulated.
Assessments
Every 3 months the DAS was assessed by a research
nurse. Questionnaires for physical function, i.e. the HAQ
[19] and short-form 36 (SF-36) [20] were completed yearly.
Side effects were documented and divided into adverse
events or serious adverse events. Serious adverse events
were defined as any adverse reaction resulting in any
of the following outcomes: a life-threatening condition
or death, a significant or permanent disability, a malig-
nancy, hospitalization or prolongation of hospitalization,
a congenital abnormality or a birth defect. Radiographs
of hands, wrists and feet were obtained at baseline, 1
and 2 years. All radiographs were read separately by
two experienced rheumatologists, who were unaware of
the identity of the patient and of the treatment group, and
the mean values were used. The radiographs were read
according to time sequence and scored according to the
Sharpvan der Heijde method [17]. Before reading the trial
radiographs, the two readers (D.vS. and Dr Pieter Prins)
separately read 22 sets of radiographs of hands and feet
from which an intra-class correlation coefficient of 95%
was calculated. BMD of the femoral neck and spine was
assessed by DXA at baseline and 2 years. The trial phys-
ician (I.C.vE.) verified adherence to the protocol every 3
months. All protocol deviations were recorded.
Endpoints
The primary endpoint was the progression of radiographic
joint damage at 2 years. Radiographic progression was
assessed in two manners: the absolute difference in
Sharp score [17, 21] and the development of new erosions
between baseline and 2 years. Erosions were diagnosed if
any individual joint incorporated in the SHS showed bone
cortex disruption on radiographs of hands and/or feet in
anteroposterior projection. Secondary endpoints included
differences between the two treatment strategies after 2
years regarding DAS, the percentage of patients in clinical
remission (DAS<1.6), HAQ and adverse events.
Sample size and statistical analysis
For the sample size calculation we looked at the appear-
ance of new erosions in the first 2 years of treatment in
152 patients of the early arthritis clinic of the Jan van
Breemen Institute who had two to five swollen joints and
no erosions at their first visit in the period before the
design of the study (19952003). Since SHSs were not
available for this group, we used the radiologist’s report
and found a frequency of 37%. We hypothesized a fre-
quency of new erosions of 10% in the aggressive group
and calculated a sample size of 80 ( =0.05, Zb=0.824,
n=38 per group leads to power 80%).
Missing data for the primary and secondary endpoints
were treated as follows: absence of a radiograph of hand
and feet or HAQ score at 2 years was defined as missing.
If a patient developed erosions on radiographs at 1 year
but the 2-year radiographs were missing, that patient was
included in the analysis as erosion developer. If a DAS
score at 2 years was lacking it was replaced by the DAS
score at 21 months (the principle of last observation car-
ried forward) if available, otherwise it was missing. All
available data were included for intention-to-treat ana-
lysis. Six patients had follow-up radiographs at 1 year
but not at 2 years. Of these, four had radiographs taken
after 3 years, and these were unchanged in comparison
with the radiographs at 1 year. Therefore the radiographic
scores in these four patients were analysed as if the radio-
graphs had been taken at 2 years. Data are expressed as
TABLE 1 Flow diagram of the possible consecutive
treatment steps in the aggressive (tight control) group
Aggressive group (n=42)
Number of
patients
MTX 15mg/week
#
MTX 25mg/week 29
#
Adalimumab 40mg/2 weeks+
MTX 25mg/week
19
#
Adalimumab 40mg/week+
MTX 25mg/week
15
#
MTX 25mg/week+SSZ 2000mg/day+
HCQ 400mg/day
11
#
MTX 25mg/week+SSZ 2000mg/day+
HCQ 400mg/day+
prednisone 7.5mg/day
3
#
LEF 20mg/day (100mg at
Day 1, 8 and 15)
1
#
Gold i.m. 50mg/week 0
#
Treating rheumatologist’s
preference
0
Therapy was aimed at achieving and maintaining a DAS
(44-joint score) <1.6. If the DAS was 51.6 at a given time
point, the therapy was changed according to this scheme. If
the DAS was <1.6 at one time point the treatment remained
unchanged. If the DAS was <1.6 at two consecutive time
points medication was tapered. The column on the right
shows the number of patients reaching the corresponding
treatment step during follow-up.
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t-test was used to compare continuous normally dis-
tributed variables between groups. Non-parametric
MannWhitney U tests were used when appropriate. For
dichotomous variables, Pearson’s chi-square test was
used. A two-tailed probability value of P<0.05 was con-
sidered statistically significant. P-values were not ad-
justed for multiple statistical tests.
Results
Patient characteristics
Randomization of 82 patients created generally balanced
groups (aggressive group n=42, conventional care group
n=40), with a mean age of 47 years and a mean symptom
duration of 6 months (Table 2). ACPA was present equally
in both groups. In the aggressive group, there was a
higher percentage of RF positivity and of fulfilment of
the 1987 ACR criteria for RA, whereas in the conventional
care group there was a higher mean DAS and CRP. Two
patients in the aggressive group discontinued adherence
to the protocol within 3 months after randomization (but
were not lost to follow-up): one patient decided directly
after randomization not to take any anti-rheumatic drugs
and one patient stopped taking MTX after an episode of
fever that required hospitalization and was ascribed to
MTX use. As this took place in the first year of the trial,
two extra patients were randomized and both were allo-
cated to the aggressive group, which explains why there
were 42 patients in the aggressive group and 40 in the
conventional care group (see also Fig. 1).
Treatment
In the aggressive group, 19 (45%) patients were eventu-
ally treated with adalimumab starting after a median of
9 months (Table 1); of these, 4 reached remission and
11 continued with the next step, 3 were still treated with
adalimumab at 2 years and 1 patient did not continue
adalimumab for fear of injections. One patient was treated
with LEF starting at 15 months, and none reached the i.m.
gold step (Table 1). In the conventional care group,
24 patients started with HCQ (subsequently 5 switched
to SSZ and 8 to MTX), 2 with SSZ and 14 with MTX
(Table 3). The mean dose of MTX among MTX users
in this group was 19mg/week. In the conventional care
group, a significantly higher number of patients received
CS injections during follow-up (18 IA and 4 i.m. injections
in 13 patients in the conventional care group vs 7 IA and
3 i.m. injections in two patients in the aggressive group,
P=0.001).
Radiography
The median SHS increase between 0 and 2 years was 0
(IQR 01.0) in the entire aggressive group and 0.25 (IQR
02.5) in the entire conventional care group (P=0.17). A
cumulative probability plot of radiographic progression in
the two groups is shown in Fig. 2. A baseline erosion with
SHS<5 (thus allowing inclusion) was present in three
patients of the aggressive group and in six patients of
the conventional care group. New erosions developed in
5 (13%) of 39 patients starting without erosions in the
aggressive group, and in 8 (24%) of 34 patients starting
without erosions in the conventional care group (P=0.25).
Data on the primary endpoint, radiographic damage at
2 years, were initially lacking in six patients. However, in
four we were able to retrieve films taken at a later date. In
all of these, the score was the same as that at 1 year,
allowing imputation. The two remaining patients were
in the conventional treatment group: both had moved
out of the area. Their SHS scores at 1 year were 0
and 4.5 (baseline score 2), respectively. In two worst-
case scenario analyses, we assumed (i) both patients
had SHS progression at 2 years; and (ii) the first
patient developed new erosions (the other patient had
baseline erosions, and thus was excluded from this ana-
lysis). The results remained non-significant (both analyses,
P=0.15).
Eight patients (three in the aggressive group and five in
the conventional care group) had an SHS increase of 55.
The characteristics of this subgroup of patients compared
with the patients with an SHS increase <5 are shown in
Table 4. Six of the eight patients received high-dose MTX
(22.525mg/week), in one case also adalimumab, for
most of the time. Three patients (all in the conventional
care group) had an SHS increase of >14 points. Two of
them were treated with high-dose MTX, one from 1 year
onward and one from 18 months onward. All three were
in DAS remission during at least four of eight measure-
ments after baseline with a mean DAS of 1.5. The primary
endpoint (SHS progression and erosion development) was
also analysed in two subgroups of patients fulfilling the
1987 ACR criteria for RA, and fulfilling the 2010
ACR/EULAR criteria for RA. In these subgroups the differ-
ences between the aggressive and conventional care
groups were unaltered (data not shown). In addition,
TABLE 2 Baseline demographic and disease characteris-
tics of the tight control and conventional care group
Characteristic
Tight control
(n=42)
Conventional
care (n=40)
Age, years 48 (13) 46 (12)
Gender: female, % 58 79
Disease duration,
months
6( 3 10) 6 (49)
IgM-RF positive, % 48 33
ACPA positive, % 60 60
DAS (44 joints) 2.2 (0.5) 2.4 (0.7)
CRP, mg/l 6 (210) 9 (321)
HAQ score 0.50 (0.250.88) 0.69 (0.321.06)
Fulfilment of 1987 ACR
criteria for RA,%
36 25
Fulfilment of 2010
ACR/EULAR criteria
for RA,%
69 68
Values are presented as mean (S.D.) or median (IQR), as
applicable.
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for change or difference between groups (data not
shown).
Disease activity, remission and functionality
Mean DAS in the aggressive group at 0 and 2 years
was 2.2 (0.52) and 1.4 (0.70), respectively, and 2.4 (0.65)
and 1.7 (0.83), respectively, in the conventional care group
(Fig. 3, upper). Mean DAS over the 2-year period
(time-averaged DAS) was 1.60 (0.60) and 1.63 (0.58) in
the aggressive and conventional care groups, respectively
(P=0.80). Remission rates in the aggressive group at 1
and 2 years were 54 and 66%, respectively, and 65 and
49% in the conventional care group (Fig. 3, middle). Seven
(17.9%) patients in the aggressive group and six (15.8%)
patients in the conventional care group reached a period
of medication-free remission (P=0.80). The median dur-
ation of medication-free remission was 6 months in the
aggressive group and 7.5 months in the conventional
care group with a range of 39 and 312 months, respect-
ively. In the aggressive group, two of seven patients had
reactivation of disease activity after medication-free re-
mission and restarted treatment with MTX. In the conven-
tional group, all patients remained medication free until
the end of the trial. The mean HAQ decrease at 2 years
compared with baseline was 0.09 (0.50) in the aggressive
group and 0.25 (0.59) in the conventional care group
(P=0.6) (Fig. 3, bottom).
A total of 28 protocol violations for varying reasons were
recorded, all in the aggressive group. Nineteen violations
were recorded due to not proceeding to the next treat-
ment step with a low DAS score just above 1.6, nine vio-
lations were caused by not tapering medication after a
third DAS <1.6. All comparisons were statistically non-
significant, both for the primary and the secondary out-
come measures.
FIG.1Consort flow diagram.
Assessed for eligibility (n=127) 
Excluded  (n=45) 
￿  Not meeting inclusion criteria (n=29) 
￿  Declined to participate (n=13) 
￿ Other  reasons  (n=3) 
Analysed  (n=42) 
Lost to follow-up (n=0) 
Discontinued intervention (n=1) 
(fear of injections)  
Allocated to aggressive group (n=42) 
￿  Received allocated intervention (n=40) 
￿  Did not receive allocated intervention 
(n=2) (see ‘Results’ section)
Lost to follow-up after Year 1 (n=2) 
(moved from area)  
Allocated to conventional care (n=40) 
￿ Received  allocated  treatment 
(n=40) 
Analysed  (n=40) 
Allocation
Analysis 
Follow-Up 
Randomized (n=82)
Enrolment
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Due to the growing recognition of the importance of ACPA
as a prognostic marker of RA, we added a subgroup ana-
lysis including only the ACPA-positive patients. In general,
the groups were comparable. Although median SHS
scores at 2 years and change of SHS score between
baseline and 2 years tended to be higher in the con-
ventional care group, values remained low and not signifi-
cantly increased compared with the aggressive group
[1 (02.5) and 1.5 (04) (P=0.4) for median SHS scores
at 2 years and 0 (02.4) and 0.5 (03.5) (P=0.3) for
change of SHS score between baseline and 2 years, in
the aggressive group and conventional care group,
respectively].
Adverse events
In the aggressive group, 59% of the patients experienced
at least one adverse event during the follow-up period vs
TABLE 3 Medication prescribed in the conventional care group
START
(n=40)
2 years 
HC (n=24)    No medication (n=6) 
) 6 = n ( C H
) 1 = n ( X T M + C H
SSZ (n=5)   SSZ  (n=3) 
MTX (n=1)  No medication (n=1) 
HC (n=1)  No medication (n=1) 
MTX (n=6)  ) 1 = n ( C H
) 3 = n ( X T M
) 2 = n ( X T M + C H
SSZ (n=2)  ) 2 = n ( X T M
MTX (n=14)     No medication (n=1) 
) 0 1 = n ( X T M
) 3 = n ( C H + SSZ + X T M
Third step Second step
This table depicts the initial therapy and number of patients receiving that therapy in the conventional care group at baseline
(first column), treatment steps within the trial period (second and third columns) and the therapy and number of patients
receiving that therapy at 2 years (fourth column).
TABLE 4 Baseline demographic and disease characteris-
tics of the subgroups of patients with a delta SHS<5
and a delta SHS 55 at 2 years compared with baseline
Characteristic
delta SHS<5
(n=68)
delta SHS55
(n=8)
Age, years 48 (4055) 36 (3155)
Gender: female, n (%) 48 (67) 7 (88)
Disease duration, months 5 (39) 7 (411)
IgM-RF positive, % 42 38
Anti-CCP positive, % 57 88
DAS (44 joints) 2.3 (1.92.7) 2.4 (1.82.7)
CRP, mg/l 8 (315) 7 (2-14)
HAQ score 0.63 (0.251.0) 0.88 (0.131.0)
Fulfilment of 1987 ACR
criteria for RA,%
29 50
Fulfilment of 2010
ACR/EULAR criteria
for RA,%
68 88
Values are presented as mean (S.D.) or median (IQR), as
applicable.
FIG.2Cumulative probability plot of radiographic
progression. Radiographic progression (Sharp/van der
Heijde units) at 2 years compared with baseline in the tight
control group (open dots) and conventional care group
(closed dots). Every dot represents a patient. The dotted
line is set at 5 Sharp/van der Heijde units as the minimal
clinically important difference.
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Aggressive therapy in early arthritis patients42% in the conventional care group (P=0.08). The total
number of adverse events was significantly higher in the
aggressive group vs the conventional care group (62 vs
35, P=0.034). Eight serious adverse events in seven pa-
tients were documented: five in the aggressive group and
three in the conventional care group. Four were medica-
tion related: three hospitalizations in the aggressive group
and one in the conventional care group. In the aggressive
group, one patient was hospitalized for fever during MTX
therapy, classified as drug-induced fever. Another patient
was hospitalized twice: once for fever during adalimumab
therapy and once for active RA and a rash based on
acute generalized exanthematous pustulosis, attributed
to adalimumab. In the conventional care group, one
patient was hospitalized for gastrointestinal problems,
which were attributed to MTX therapy.
Discussion
In this trial of an aggressive vs a conventional approach to
early arthritis of two to five joints, most patients had an
excellent outcome with respect to disease activity, func-
tionality and radiographic damage regardless of the treat-
ment group they were randomized to. A minority of
patients in both groups experienced radiographic pro-
gression despite treatment with higher dose MTX and
despite being in remission at most time points. There
were also a substantial number of adverse events, espe-
cially in the aggressive group.
The radiological results (Fig. 2) give rise to the expect-
ation that the difference between the groups would have
been significant (in favour of the aggressive group) if the
sample size had been larger, thus suggesting a lack of
statistical power. In addition, not all patients had radio-
graphs at the 2-year point. In our view, the main reason for
the lack of statistically significant differences in the out-
come parameters between the groups is that the gradual
intensification of the conventional care during the course
of the study, including a higher number of CS injections in
that group, led to less contrast in therapy between the
groups and to a lower than originally expected rate of
radiographic damage in the conventional care group
(24% observed instead of 37% expected new erosions),
whereas the aggressive group achieved a 13% rate of
new erosions, which is near to the 10% that had been
assumed for the power calculation. The general trend in
the treatment of (rheumatoid) arthritis is towards earlier
and more aggressive treatment. At the time the study
was designed in 2003, both study arms were acceptable
for the participating rheumatologists. During the study,
however, the conventional care needed to be intensified
to accommodate changing views, and presently even
the aggressive arm is considered to be not so aggressive,
since adalimumab therapy was postponed until 6 months
in non-responders. Furthermore, although ACPA positiv-
ity was equal among the groups, the study was not
designed to separately analyse ACPA-positive and -nega-
tive subgroups, which were less prominently seen as
important subgroups during the design phase of the
study.
There were some drawbacks to using DAS-steered
treatment aiming for remission (DAS<1.6). Three patients
had significant radiographic progression, although they
were in DAS remission most of the time. As has been
noted before, clinical remission is no guarantee for radio-
logical remission [22], although a recent review showed
that patients who achieve remission, defined in any way,
will generally develop less radiological damage and
deterioration of physical function compared with patients
not reaching remission [23]. Secondly, it occurred a few
times during the course of the study that patients without
any swollen joints would proceed to the next step of
high-dose MTX or adalimumab because they had a DAS
51.6 due to a high value of the DAS component of
patient-reported general health. In a number of cases,
based on this, the treating physician refused to intensify
treatment. In light of the intensity of treatment needed to
FIG.3Secondary endpoints for DAS and HAQ in the
aggressive group and the conventional care group.
Upper: mean DASs at each time point. Middle: remission
rates (percentage of patients with DAS<1.6) at each time
point. Bottom: median HAQ scores at baseline, 1 and
2 years. Open dots represent the tight-control group
and closed dots represent the conventional care group.
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Izhar C. van Eijk et al.achieve these results, the number of adverse events that
occurred (in both groups, but more so in the aggressive
group) calls to mind the task of the physician to weigh the
possible benefits of treatment against the possibility of
causing harm. A related issue is the value of the DAS as
a measure of remission in RA; although the DAS can be
>1.6 while joints are neither swollen nor tender, the
opposite also occurs: a patient reaches DAS remission
in the presence of tender and/or swollen joints. In this
case, one might better speak of minimal disease activity
rather than remission [24]. Although most patients treated
with biologic therapies seem to experience a virtual halt of
radiographic progression, regardless of disease activity,
even with biologic agents, a slight progression of joint
damage can be observed with increasing disease activity
[25, 26]. A problem is that current methods, such as the
SHS, for identifying progression are insensitive in the set-
ting of very low progression rates, since the smallest de-
tectable difference is 5 SHS points [21]. Furthermore,
clinical methods are also unreliable in the setting of very
low disease activity. Subclinical joint inflammation, which
can be detected by US and MRI in patients in clinical re-
mission can mostly explain any ongoing radiographic pro-
gression [27]. It therefore remains possible that the
observed reduction in association between disease activ-
ity and radiological damage is in fact explained by sub-
clinical synovitis. This brings up the question, what is real
remission? For this purpose, the ACR and EULAR have
recently constituted a committee charged with the task to
redefine remission in RA [28].
Other trials in early oligoarthritis or UA have noted some
benefit from treatment with i.m. or IA CSs compared with
placebo or NSAIDs [29, 30], although a recent study
observed that neither remission nor development of RA
was delayed by i.m. glucocorticoid treatment [31]. Three
months of infliximab did not prevent progression to RA
[32] after 1 year, nor did abatacept monotherapy [33],
although abatacept had an impact on radiographic and
MRI inhibition, which was maintained for 6 months after
treatment stopped. MTX was successful in postponing the
diagnosis of RA after 1.5 years, as well as in retarding
radiological damage [15]. The positive results of the
latter study were confined to the subgroup of
ACPA-positive patients. In these trials, adverse events
were generally not a problem.
Since the present study has not demonstrated a func-
tional or radiological benefit of aggressive over conven-
tional treatment, we cannot recommend aggressive
therapy in all patients presenting with two to five swollen
joints. The benefit of aggressive treatment in early inflam-
matory arthritis is not as evident as it is in polyarthritis, and
many patients achieved good results, including prevention
of erosive disease, with HCQ only, as has been found
before in early RA [16, 34]. The treatment of oligoarthritis
should ideally depend on an accurate prediction of
prognosis. The most important prognostic factors are
ACPA and radiographic damage [35]. These data, com-
bined with the results of the present study, may suggest
that in patients with early inflammatory arthritis a
radiographic-driven therapy may be superior to the widely
used DAS-driven therapy in reducing structural joint
damage, but more research is needed to further refine pre-
diction and thus guide therapy at the individual level.
Rheumatology key messages
. Aggressive therapy in patients with early arthritis
results in similar outcome compared with conven-
tional care.
. In early arthritis radiographic-driven therapy may be
superior to DAS-driven therapy in reducing struc-
tural joint damage.
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